Boogaerts MA - Search Results

1

Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features.

Verhoef GE, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M, Zacheé P, Cassiman JJ, Van den Berghe H, Boogaerts MA. Verhoef GE, et al. Among authors: boogaerts ma. Ann Hematol. 1991 Nov;63(5):235-41. doi: 10.1007/BF01698371. Ann Hematol. 1991. PMID: 1958747

2

Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature.

Verhoef G, Meeus P, Stul M, Mecucci C, Cassiman JJ, Van Den Berghe H, Boogaerts M. Verhoef G, et al. Cancer Genet Cytogenet. 1992 Apr;59(2):161-6. doi: 10.1016/0165-4608(92)90209-q. Cancer Genet Cytogenet. 1992. PMID: 1581881 Review.

3

Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors.

Verhoef G, Van den Berghe H, Boogaerts M. Verhoef G, et al. Leukemia. 1992 Aug;6(8):766-9. Leukemia. 1992. PMID: 1640727

4

Update on the prognostic implication of morphology, histology, and karyotype in primary myelodysplastic syndromes.

Verhoef G, De Wolf-Peeters C, Kerim S, Van De Broeck J, Mecucci C, Van den Berghe H, Boogaerts M. Verhoef G, et al. Hematol Pathol. 1991;5(4):163-75. Hematol Pathol. 1991. PMID: 1794966

5

Application of the International Prognostic Scoring System for myelodysplastic syndromes.

Maes B, Meeus P, Michaux L, Bijnens L, Boogaerts M, Hagemeijer A, De Wolf-Peeters C, Verhoef G. Maes B, et al. Ann Oncol. 1999 Jul;10(7):825-9. doi: 10.1023/a:1008335814674. Ann Oncol. 1999. PMID: 10470430 Free article.

6

Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Verhoef GE, Zachée P, Ferrant A, Demuynck H, Selleslag D, Van Hove L, Deckers F, Boogaerts MA. Verhoef GE, et al. Among authors: boogaerts ma. Ann Hematol. 1992 Jan;64(1):16-21. doi: 10.1007/BF01811466. Ann Hematol. 1992. PMID: 1739754

7

Risks of rhG-CSF treatment in drug-induced agranulocytosis.

Demuynck H, Zachée P, Verhoef GE, Schetz M, Van den Berghe G, Lauwers P, Boogaerts MA. Demuynck H, et al. Among authors: boogaerts ma. Ann Hematol. 1995 Mar;70(3):143-7. doi: 10.1007/BF01682034. Ann Hematol. 1995. PMID: 7536476

8

FAB classification of myelodysplastic syndromes: merits and controversies.

Verhoef GE, Pittaluga S, De Wolf-Peeters C, Boogaerts MA. Verhoef GE, et al. Among authors: boogaerts ma. Ann Hematol. 1995 Jul;71(1):3-11. doi: 10.1007/BF01696227. Ann Hematol. 1995. PMID: 7632816 Review.

9

Hematologic aspects of end-stage renal failure.

Zachée P, Vermylen J, Boogaerts MA. Zachée P, et al. Among authors: boogaerts ma. Ann Hematol. 1994 Jul;69(1):33-40. doi: 10.1007/BF01757345. Ann Hematol. 1994. PMID: 8061105 Review.

10

Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemia.

Van de Casteele M, Verhoef GE, Demuynck H, Zacheé P, Boogaerts MA. Van de Casteele M, et al. Among authors: boogaerts ma. Ann Hematol. 1994 Aug;69(2):79-80. doi: 10.1007/BF01698486. Ann Hematol. 1994. PMID: 8080883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters